

Table S1. Demographic characteristics at baseline, stratified by pediatric kidney transplant recipients vs healthy volunteers.

Parameters	Kidney transplant recipients (n = 78)	Pediatric healthy volunteers (n = 103)	p-value
Median age, years (IQR)	15 (14 – 16)	14 (13 – 15)	< 0.0001
Age category, n (%)			
12 – 15 years	40 (52)	82 (80)	0.0001
16 – 18 years	38 (48)	21 (20)	
Male gender, n (%)	45 (58)	58 (56)	0.788
Comorbidities, n (%)			
Hypertension	24 (31)	0	< 0.0001
Previous posttransplant lymphoproliferative disease	4 (5)	0	< 0.0001
Thrombophilia	2 (3)	0	< 0.0001
Retransplants, n (%)	4 (5)	-	-
Deceased donor transplant, n (%)	76 (97)	-	-
Median length of transplant, years (IQR)	3 (1.2 – 6.4)	-	-
Up to 6 months, n (%)	3 (4)	-	-
6 – 12 months, n (%)	15 (19)	-	-
More than 12 months, n (%)	60 (77)	-	-
Maintenance immunosuppression, n (%)		-	-
TAC-Pred-AZA	54 (69)	-	-
CSA-Pred-AZA	6 (8)	-	-
TAC-Pred-MPA	11 (13)	-	-
TAC-Pred-mTORi	2 (3)	-	-
mTORi-Pred	3 (4)	-	-
TAC-Pred	2 (3)	-	-
Pulse methylprednisolone for acute rejection in the past 6 months, n (%)	4 (5)	-	-
Current plasmapheresis plus rituximab therapy for recurrent FSGS, n (%)	1 (1)	-	-

IQR, interquartile range; TAC, tacrolimus; Pred, prednisone; CSA, cyclosporine; AZA, azathioprine; MPA, mycophenolic acid; mTORi, inhibitors of the mammalian target of rapamycin; FSGS, focal segmental glomerulosclerosis.

Figure S1. IgG anti-SARS-CoV-2 values before and after the second dose of BNT162b2 vaccine among pediatric kidney transplant recipients (pink) and healthy pediatric volunteers (blue).

Median IgG-anti-SARS-CoV-2 before (1453 AU/mL [n=53] vs. 5,641 AU/mL [n=103], $p=0.014$) and at least 28 days after (10,240 AU/mL [n=78] vs 13 771 AU/mL [n=103], $p=0.168$) the second dose of BNT162b2 vaccine among pediatric kidney transplant recipients and healthy pediatric population.

Abbott Architect SARS-CoV-2 IgG II immunoassay for total IgG antibodies against the receptor binding domain of the S1-subunit of the SARS-CoV-2 spike protein, in logarithmic scale. The lowest limit of detection (LoD) by the manufacturer is 6.8 AU/mL (0.83 log), and the analytical measuring interval is 21 (1.32 log, LoQ) to 40 000 (4.60 log) AU/mL. The threshold for considering the test as positive is 50 AU/mL, or 1.69log (dotted line).

